{"id":"NCT02979639","sponsor":"GlaxoSmithKline","briefTitle":"Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age","officialTitle":"Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GSK Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-01-16","primaryCompletion":"2017-04-12","completion":"2018-05-24","firstPosted":"2016-12-01","resultsPosted":"2018-10-16","lastUpdate":"2019-10-08"},"enrollment":404,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Herpes Zoster"],"interventions":[{"type":"BIOLOGICAL","name":"GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)","otherNames":[]}],"arms":[{"label":"GSK1437173A Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the impact of reactogenicity of GSK Biologicals' HZ/su vaccine on Quality of Life (QoL) in adults ≥ 50 years of age","primaryOutcome":{"measure":"Change in the Short Form 36-item-health Survey (SF36) Physical Functioning (PF) From Baseline Score to Mean Score After First Dose","timeFrame":"From Baseline at Day -7 to Day 8 after first dose","effectByArm":[{"arm":"GSK1437173A Group","deltaMin":1.9,"sd":10.44}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":11,"countries":["United States"]},"refs":{"pmids":["30256905"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":401},"commonTop":["Injection site pain","Fatigue","Headache","Myalgia","injection site erythema"]}}